A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
about
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.Studies on DNA Damage Repair and Precision Radiotherapy for Breast Cancer.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Advances in the use of PARP inhibitor therapy for breast cancerTargeted treatment of advanced ovarian cancer: spotlight on rucaparib
P2860
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A phase I study of intravenous ...... ts with advanced solid tumours
@ast
A phase I study of intravenous ...... ts with advanced solid tumours
@en
type
label
A phase I study of intravenous ...... ts with advanced solid tumours
@ast
A phase I study of intravenous ...... ts with advanced solid tumours
@en
prefLabel
A phase I study of intravenous ...... ts with advanced solid tumours
@ast
A phase I study of intravenous ...... ts with advanced solid tumours
@en
P2093
P2860
P356
P1476
A phase I study of intravenous ...... ts with advanced solid tumours
@en
P2093
Heidi Giordano
L Rhoda Molife
Mark R Middleton
Patricia Roxburgh
Richard H Wilson
Ruth Plummer
Sandra Goble
Sarah Jaw-Tsai
Tr Jeffry Evans
Veronique Dieras
P2860
P2888
P304
P356
10.1038/BJC.2017.36
P407
P50
P577
2017-02-21T00:00:00Z
P6179
1083853536